Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
0.916
-0.005 (-0.59%)
At close: Dec 20, 2024, 4:00 PM
0.958
+0.042 (4.64%)
After-hours: Dec 20, 2024, 6:36 PM EST
Seres Therapeutics Revenue
Seres Therapeutics had revenue of $126.33M in the twelve months ending September 30, 2024, up 12,856.41% year-over-year. In the year 2023, Seres Therapeutics had annual revenue of $126.33M with 1,672.24% growth.
Revenue (ttm)
$126.33M
Revenue Growth
+12,856.41%
P/S Ratio
1.05
Revenue / Employee
$542,167
Employees
233
Market Cap
156.31M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 126.33M | 119.20M | 1,672.24% |
Dec 31, 2022 | 7.13M | -137.80M | -95.08% |
Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
ModivCare | 2.79B |
Nutex Health | 292.00M |
Sutro Biopharma | 160.96M |
The Joint | 120.80M |
Fennec Pharmaceuticals | 49.35M |
Nanobiotix | 45.22M |
Cellectis | 36.04M |
MCRB News
- 5 days ago - Seres Therapeutics to Participate in 2025 J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 weeks ago - Seres Therapeutics to Participate in Piper Sandler Healthcare Conference - GlobeNewsWire
- 5 weeks ago - Seres Therapeutics, Inc. (MCRB) Q3 2024 Earnings Call Transcript - Seeking Alpha
- 6 weeks ago - Seres Therapeutics to Announce Third Quarter 2024 Financial Results and Business Updates on November 13, 2024 - GlobeNewsWire
- 2 months ago - Seres Therapeutics Announces Completion of VOWST™ Asset Sale to Société des Produits Nestlé S.A - GlobeNewsWire
- 3 months ago - Seres Therapeutics Stockholders Issue Open Letter to Board of Directors Regarding Reported Engagement With Nestlé - Business Wire
- 3 months ago - Seres Therapeutics Stockholders Approve Sale of VOWST™ to Nestlé Health Science; Sale Expected to Close on September 30 - GlobeNewsWire
- 3 months ago - Seres Therapeutics' Strategic Sale Of Vowst Warrants A Rating Upgrade - Seeking Alpha